Literature DB >> 20160469

Comparison between immunoradiometric and fluorimetric brain natriuretic peptide determination in patients with congestive heart failure.

M Feola1, L Valeri, E Menditto, E Nervo, F Bianco, N Aspromonte, R Valle, G Visconti.   

Abstract

UNLABELLED: This study compared two different methods, namely the immunoradiometric (IRMA) and fluorimetric (FIA), in order to determine plasma brain natriuretic peptide (BNP) in congestive heart failure (CHF) patients.
METHODS: CHF in-patients underwent echocardiography and plasma BNP determination using both two methods. The echocardiograms analysed left ventricular end-systolic (LVESV) and end-diastolic (LVEDV) volumes and systolic dysfunction [left ventricular ejection fraction (LVEF) <50%].
RESULTS: Seventy-three (71% males, age 67 ± 9.6 yr) patients were enrolled, 31.5% affected by valvular heart disease. The mean LVEF was 39.8 ± 14.1%; in 26 (35%) a hypertensive etiology emerged. The immunoradiometric assay (IRMA) BNP was found to be significantly lower than the FIA determination 116.5 ± 149 pg/ml vs 267.3 ± 285.6 pg/ml; p=0.0001) and the two methods were closely correlated (r=0.89; p=0.00001). Logistic regression demonstrated a significant correlation between BNP, LVEF, and LVESV/LVEDV (r=-0.45, p=0.0003; r=-0.48, p=0.00001; r=0.22 p=0.003; r=0.34 p=0.0001; r=0.13 p=0.02; r=0.28 p=0.001 IRMA and FIA, respectively). IRMA BNP and FIA BNP significantly increased according to the worsening functional class [from 34.3 ± 60.2 pg/ml in NYHA (New York Heart Association) I to 555.5 ± 273.1 pg/ml in NYHA IV; from 86.1 ± 162.1 pg/ml in NYHA I to 1070 ± 42.2 pg/ml in NYHA IV, respectively]. In severe systolic dysfunction (LVEF<30%), receiver operating characteristic analysis revealed a satisfactorily sensitivity and specificity using a cut-off point of 50.6 pg/ml with IRMA and 243 pg/ml with FIA. In mild systolic dysfunction (LVEF<50%), a good sensitivity and specificity using a cut-off point of 42 pg/ml with IRMA and 182 pg/ml with FIA emerged.
CONCLUSIONS: In CHF patients both BNP methods correlated with NYHA class, LVEF, and ventricular volumes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20160469     DOI: 10.1007/BF03346647

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  26 in total

1.  Evaluation of a new, rapid bedside test for quantitative determination of B-type natriuretic peptide.

Authors:  Y Fischer; K Filzmaier; H Stiegler; J Graf; S Fuhs; A Franke; U Janssens; A M Gressner
Journal:  Clin Chem       Date:  2001-03       Impact factor: 8.327

2.  Guidelines for the diagnosis and treatment of chronic heart failure.

Authors:  W J Remme; K Swedberg
Journal:  Eur Heart J       Date:  2001-09       Impact factor: 29.983

3.  Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings.

Authors:  Emily Lubien; Anthony DeMaria; Padma Krishnaswamy; Paul Clopton; Jen Koon; Radmila Kazanegra; Nancy Gardetto; Erin Wanner; Alan S Maisel
Journal:  Circulation       Date:  2002-02-05       Impact factor: 29.690

4.  Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure.

Authors:  A Clerico; G Iervasi; M G Del Chicca; M Emdin; S Maffei; M Nannipieri; L Sabatino; F Forini; C Manfredi; L Donato
Journal:  J Endocrinol Invest       Date:  1998-03       Impact factor: 4.256

Review 5.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms.

Authors:  N B Schiller; P M Shah; M Crawford; A DeMaria; R Devereux; H Feigenbaum; H Gutgesell; N Reichek; D Sahn; I Schnittger
Journal:  J Am Soc Echocardiogr       Date:  1989 Sep-Oct       Impact factor: 5.251

6.  B-type natriuretic peptide in organic mitral regurgitation: determinants and impact on outcome.

Authors:  Delphine Detaint; David Messika-Zeitoun; Jean-François Avierinos; Christopher Scott; Horng Chen; John C Burnett; Maurice Enriquez-Sarano
Journal:  Circulation       Date:  2005-05-10       Impact factor: 29.690

7.  Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population.

Authors:  M Nakamura; H Endo; M Nasu; N Arakawa; T Segawa; K Hiramori
Journal:  Heart       Date:  2002-02       Impact factor: 5.994

8.  Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea.

Authors:  L Katherine Morrison; Alex Harrison; Padma Krishnaswamy; Radmila Kazanegra; Paul Clopton; Alan Maisel
Journal:  J Am Coll Cardiol       Date:  2002-01-16       Impact factor: 24.094

9.  Elevated B-type natriuretic peptide despite normal left ventricular function on rest and exercise stress echocardiography in mitral regurgitation.

Authors:  Andrew J Kerr; O Christopher Raffel; Gillian A Whalley; Irene Zeng; Ralph A Stewart
Journal:  Eur Heart J       Date:  2008-01-17       Impact factor: 29.983

Review 10.  Pathophysiological and clinical relevance of circulating levels of cardiac natriuretic hormones: are they merely markers of cardiac disease?

Authors:  Aldo Clerico
Journal:  Clin Chem Lab Med       Date:  2002-08       Impact factor: 3.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.